PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

NAD+: Research & Evidence

Emerging Evidence

Published research, clinical trial data, and evidence grading for NAD+ across studied indications.

Back to NAD+ overview

Evidence by Indication (3 indications)

Indication Tier Trials Summary
Cellular aging Tier B 8 Growing human trial evidence for NMN/NR supplementation
Energy metabolism Tier B 6 Consistent improvements in mitochondrial function markers
Neuroprotection Tier C 5 Preclinical data strong, human data emerging

Graded using our evidence tier methodology.

Citations (5 sources)

  1. 1. Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure. Study

    (2025), Nature cancer

  2. 2. Phages reconstitute NAD Study

    (2024), Nature

  3. 3. LXR/CD38 activation drives cholesterol-induced macrophage senescence and neurodegeneration via NAD Study

    (2024), Cell reports

  4. 4. Nicotinamide Mononucleotide Supplementation Improves Mitochondrial Dysfunction and Rescues Cellular Senescence by NAD Study

    (2022), International journal of molecular sciences

  5. 5. Macrophage de novo NAD Study

    (2019), Nature immunology